LogicBio Therapeutics (OTCMKTS:LOGC) Shares Down 0.7% – Time to Sell?

LogicBio Therapeutics, Inc. (OTCMKTS:LOGC) was down 0.7% during trading on Monday . The stock traded as low as $8.99 and last traded at $8.99. 20,183 shares were traded during trading, a decline of 84% from the average session volume of 123,435 shares. The stock had previously closed at $9.05.

Analyst Ratings Changes

Separately, Wall Street Zen downgraded LogicBio Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, March 29th.

LogicBio Therapeutics Stock Performance

The company’s fifty day simple moving average is $9.00 and its two-hundred day simple moving average is $8.38. The company has a debt-to-equity ratio of 0.28, a quick ratio of 1.15 and a current ratio of 1.67. The stock has a market capitalization of $416.14 million, a P/E ratio of -8.35 and a beta of 2.01.

Institutional Inflows and Outflows

An institutional investor recently raised its position in LogicBio Therapeutics stock. Goldman Sachs Group Inc. grew its holdings in LogicBio Therapeutics, Inc. (OTCMKTS:LOGC) by 284.9% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 526,673 shares of the company’s stock after acquiring an additional 389,843 shares during the quarter. Goldman Sachs Group Inc. owned 2.00% of LogicBio Therapeutics worth $3,676,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 46.05% of the company’s stock.

About LogicBio Therapeutics

LogicBio Therapeutics, Inc, a genetic medicine company, focuses on developing and commercializing genome editing and gene therapy treatments using its GeneRide and sAAVy platforms. The company's GeneRide technology is a new approach to precise gene insertion harnessing a cell's natural deoxyribonucleic acid; and gene delivery platform, sAAVy is an adeno-associated virus, which is designed to optimize gene delivery for treatments in a range of indications and tissues. Its lead product candidate is LB-001 that is in Phase I/II clinical trials for the treatment of methylmalonic acidemia.